homeless or lack general knowledge about the services available to them or how the system works.

Therefore, ADD is proposing to fund Projects of National Significance (PNS) that target individuals with developmental disabilities and their families from culturally diverse backgrounds in an effort to enable them to impact service delivery and fully access the services they need. These projects would strengthen the ability of individuals with developmental disabilities and their families from culturally diverse backgrounds to serve as leaders and advocates on critical issues in the developmental disabilities field, particularly in their own communities. These projects would assist individuals with developmental disabilities from culturally diverse backgrounds and their families in the development and implementation of effective methods of communication and systems change to increase public awareness, inform individuals from culturally diverse backgrounds with disabilities of issues and services, and to develop and to implement networking strategies that improve access to community resources. Furthermore, these projects would institutionalize action strategies that promote policies and practices which are family-centered and community-based.

ADD is particularly interested in grassroots organizations with a record of planning and implementing programs with individuals from culturally diverse backgrounds, such as major civil rights organizations, minority coalitions, and other private non-profits that would be able to establish ongoing working relationships with State Developmental Disabilities Planning Councils, University Affiliated Programs, Protection and Advocacy Systems and other relevant community resources.

It is essential to identify local linkages to establish collaborative agreements/arrangements on critical issues in the developmental disabilities field that would strengthen the capacity of individuals to serve as leaders/advocates on behalf of themselves and their families.

Every effort will be made to coordinate the activities under this priority areas with the Department of Education and other Federal agencies.

Proposed Fiscal Year 1994 Priority Area 2: Expanding the Scope of Developmental Disabilities Planning Councils

Individuals with significant disabilities other than developmental disabilities can and have benefitted from the systems change, capacity building and advocacy activities of the Developmental Disabilities Planning Councils (DDPCs) authorized by Part B of the Act. In response to concerns of some advocates in the States, ADD proposes to award funds to study the expansion of the scope of DDPCs to include concerns of a broad range of citizens with disabilities other than developmental disabilities. Because this issue is complex and little information is available regarding the implications of such an expansion, ADD is interested in funding three types of projects to explore the effects of such an expansion:

- A short-term (not to exceed six months) study of DDPCs that are currently authorized under State law to focus on individuals with disabilities other than developmental disabilities as well as persons with developmental disabilities.
- Pilot studies in up to five (5) additional states by DDPCs, in conjunction with and with support from Protection and Advocacy systems and University Affiliated Programs, to explore the implications of expanding the current scope of Council activity. Pilots are expected to be completed within 15 months.
- A national study of the process, outcomes, and implications of the five (5) pilot studies. Completion of this study is expected five months following the pilots.

Under separate contractual solicitations, ADD proposes to award funds to provide technical assistance to improve the functions of the DD Council, Protection and Advocacy System, and the University Affiliated Program; and to develop information and referral systems.

ADD also proposes to fund projects through demonstrations as well as procurements that would ensure the integration and active participation of racial and ethnic minorities into the "mainstream" of the service delivery system.

(Federal Catalog Domestic Assistance Number 13.631 Developmental Disabilities—Projects of National Significance)

Dated: Janaury 14, 1994.

Bob Williams,

Commissioner, Administration on Developmental Disabilities.

[FR Doc. 94–4103 Filed 2–23–94; 8:45 am]

BILLING CODE 4184–01–P

Centers for Disease Control and Prevention

Chorionic Villus Sampling Meeting

The National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Chorionic Villus Sampling (CVS) Meeting.

Time and Date: 8:30 a.m.–5 p.m., Friday, March 11, 1994.

Place: CDC, Auditorium A, 1600 Clifton Road, NE., Atlanta, Georgia 30333.

Status: Open to public for observation and comment, limited only by space available.

Purpose: CVS is an obstetrical diagnostic procedure done prenatally to detect genetic abnormalities. The safety of the procedure has been questioned since infants have been reported with birth defects (limb deficiency) after their mothers had undergone CVS. Studies have been published which both support and contradict the hypothesis that CVS has caused birth defects. CDC has recently completed a multistate study investigating the association between limb deficiency and CVS. CDC will convene this public meeting to discuss all recent studies of this issue and to receive advice from individual participants on establishing public health recommendations for CVS utilization.

Matters to Be Discussed: An invited group of qualified individuals will be asked to provide comments on recent studies of limb deficiency after CVS. The risk for these birth defects will be discussed in the context of other risks, benefits, and alternatives of the procedure. A written commentary from CDC which provides recommendations for CVS utilization will also be discussed.

Contact Person for More Information: J. David Erickson, D.D.S., Ph.D., Chief, Birth Defects and Genetic Diseases Branch, Division of Birth Defects and Developmental Disabilities, NCEH, CDC, Mailstop F–45, 4770 Buford Highway, NE, Atlanta, Georgia 30341–3724, telephone 404/488–7160.

Dated: February 17, 1994.

Elvin Hilyer,

Associate Director for Policy Coordination, Centers for Disease Control and Prevention (CDC).

[FR Doc. 94–4124 Filed 2–23–94; 8:45 am]

BILLING CODE 4163–18–M

Technical Advisory Committee for Diabetes Translation and Community Control Programs; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Technical Advisory Committee for Diabetes Translation and Community Control Programs.

Time and date: 8:30 a.m.–4 p.m., Monday, March 14, 1994.

Place: Sheraton Gateway Hotel, 1900 Sullivan Road, College Park, Georgia 30337.

Status: Open to the public, limited only by the space available.

Purpose: This committee is charged with advising the Director, CDC, regarding

priorities and feasible goals for translation activities and community control programs designed to reduce risk factors, morbidity and mortality associated with diabetes and its complications. The committee advises regarding policies, strategies, goals and objectives, and priorities; identifies research advances and technologies ready for translation into widespread community practice; recommends public health strategies to be implemented through community interventions; advises on operational research and outcome evaluation methodologies; identifies research issues for further clinical investigation; and advises regarding the coordination of programs with Federal, voluntary, and private resources involved in the provision of services to people with diabetes.

Matters to be discussed: The committee will discuss the status of the Request for Application that will be issued for award in June 1994 and the expansion of state-based diabetes control programs. The committee will review and provide input on Project DIRECT (Diabetes Intervention: Reaching and Educating Communities Together), social marketing, and the Health Communications Plan. The committee will discuss national diabetes surveillance and future conference strategies. Committee members will make recommendations to the Division of Diabetes Translation on coordination and implementation of diabetes translation activities and the role of the committee within this coordination process. Division of Diabetes Translation staff will provide updates on projects and initiatives currently operational within the Division.

Agenda items are subject to change as priorities dictate.

Contact person for more information: Cheryl Counts, Program Specialist, Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, NE., (K–10), Atlanta, Georgia 30341–3724, telephone 404/488–5004.

Dated: February 16, 1994.

Elvin Hilyer,

Associate Director for Policy Coordination, Centers for Disease Control and Prevention (CDC).

[FR Doc. 94–4123 Filed 2–23–94; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 94F–0008]

Analytical Systems Engineering Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Analytical Systems Engineering Corp. (ASEC) has filed a petition proposing that the food additive regulations be amended to provide for the safe use of a machine source of high energy X-rays to inspect cargo containers which may contain food.

DATES: Written comments on the petitioner's environmental assessment by March 28, 1994.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Patricia A. Hansen, Center for Food Safety and Applied Nutrition (HFS–206), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–254–9523.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 4M4407) has been filed by Analytical Systems Engineering Corp., 5400 Shawnee Rd., suite 100, Alexandria, VA 22312. The petition proposes that the food additive regulations in § 179.21 *Sources of radiation used for inspection of food, for inspection of packaged food, and for controlling food processing* (21 CFR 179.21) be amended to provide for the safe use of a machine source of high energy X-rays to inspect cargo containers which may contain food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before March 28, 1994, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: February 10, 1994.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 94–4077 Filed 2–23–94; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 94N–0005]

Ciba-Geigy Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ciba-Geigy Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of oxidized bis(hydrogenated tallow alkyl)amines as a process stabilizer for polypropylene intended for use in contact with food.

DATES: Written comments on the petitioner's environmental assessment by March 28, 1994.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Daniel N. Harrison, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204–0002, 202–254–9500.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 4B4410) has been filed by Ciba-Geigy Corp., Seven Skyline Dr., Hawthorne, NY 10532. The petition proposes that the food additive regulations in § 178.2010 *Antioxidants and/or stabilizers for polymers* (21 CFR 178.2010) be amended to provide for the safe use of oxidized bis(hydrogenated tallow alkyl)amines (CAS Reg. No. 143925–92–2) as a process stabilizer for polypropylene intended for use in contact with food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition

that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before March 28, 1994, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: February 15, 1994.

Janice F. Oliver,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 94–4080 Filed 2–23–94; 8:45 am]

BILLING CODE 4160–01–F

Health Resources and Services Administration Advisory Council; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), announcement is made of the following National Advisory body scheduled to meet during the month of April 1994.

Name: Departments of Family Medicine Review Committee.

Date and Time: April 4–6, 1994, 8:30 a.m.

Place: Holiday Inn Crowne Plaza, Regency Room, 1750 Rockville Pike, Rockville, Maryland 20852.

Open on April 4, 8:30 a.m.–9:30 a.m.

Closed for Remainder of Meeting.

Purpose: The Departments of Family Medicine Review Committee shall review applications that assist in meeting the costs of establishing, maintaining, or improving academic administrative units (which may be departments, divisions, or other units) to provide clinical instruction in family medicine.

Agenda: The open portion of the meeting will cover welcome and opening remarks, financial management and legislative implementation updates, and overview of the review process. The meeting will be closed to the public on April 4, at 11 a.m. for the remainder of the meeting for the review of grant applications. The closing is in accordance with the provisions set forth in section 552b(c)(6), title 5 U.S.C., and the Determination by the Associate Administrator for Policy Coordination, Health Resources and Services Administration, pursuant to Public Law 92–463.

Anyone wishing to obtain a roster of members, minutes of meeting, or other relevant information regarding the subject Committee should contact Mrs. Sherry Whipple, Executive Secretary, Departments of Family Medicine Review Committee, room 4C–18, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443–6874.

Agenda Items are subject to change as priorities dictate.

Dated: February 17, 1994.

Jackie E. Baum,

Advisory Committee Management Officer, HRSA.

[FR Doc. 94–4082 Filed 2–23–94; 8:45 am]

BILLING CODE 4160–15–P

National Institutes of Health

Meetings of Panel/Request for Public Comment

Notice is hereby given of the future meeting dates of the National Institutes of Health (NIH) Human Embryo Research Panel, a panel of special consultants to the Advisory Committee to the Director (ACD), NIH, established to recommend guidelines for Federal funding of human embryo research. Panel meetings will be held March 14, April 11, May 4, and, tentatively, June 21. The March meeting will be held from 8:30 a.m. to 6 p.m. at the Bethesda Marriott Hotel, 5151 Pooks Hill Road, Bethesda, Maryland. Logistical information about subsequent Panel meetings will be available from the contact office listed below.

Until June 1993, Federal regulations governing research on human subjects (45 CFR part 46) required research involving *in vitro* fertilization (IVF) to be reviewed by an Ethics Advisory Board (EAB). Because of the absence of an EAB since 1980, Federal funding of IVF protocols was not possible. With the enactment of the NIH Revitalization Act of 1993 (Pub. L. 103–43), the regulatory provision requiring EAB review of IVF proposals was nullified. As a result, IVF proposals, as well as research involving human embryos that result from IVF or other sources, may now be considered for Federal funding.

The NIH has received a number of applications for support in this area and in the related field of parthenogenesis. However, before proceeding with the consideration of specific human embryo research proposals for funding, the NIH must address the profound moral and ethical issues raised by the use of human embryos in research and develop guidelines to govern the review and conduct of Federally-funded research. Panel members will be asked to consider various areas of research involving the human embryo and provide advice as to those areas they view to be acceptable for Federal funding, areas that warrant additional review, and areas that are unacceptable for Federal support. For those areas of research considered acceptable for Federal funding, the Panel will be asked to recommend specific guidelines for the review and conduct of this research. Issues related to human germ-line gene modification are not within the Panel's purview. The Panel's final report will be presented to the ACD for review.

A critical part of the process of considering these issues is to gain an understanding of the diversity of beliefs and opinions held about the moral status of the human embryo and about Federal funding of research involving the human embryo. The NIH is seeking public comment on Federal funding of human embryo research for consideration by the Panel and encourages interested individuals and organizations to share with the Panel their views and perspectives on this important topic. Those who wish to submit written comments of any length should forward these to Steven Muller, Ph.D., Chair, NIH Human Embryo Research Panel, c/o National Institutes of Health, 9000 Rockville Pike, Building #1, room 218, Bethesda, Maryland 20892. To ensure that public input is available to the Panel during its deliberations, written comments should be received in advance of the Panel's fourth scheduled meeting, May 4, 1994.

Each meeting of the Panel will also provide an opportunity for interested individuals and organizations to make brief oral presentations to the Panel. During the first Panel meeting, public commentary was heard in a two-hour session. To register to make an oral statement before the Panel, individuals and organizations should contact Ms. Peggy Schnoor at the NIH by telephoning 301–496–1454 or by sending a facsimile message to 301–402–0280 or 301–402–1759. Oral statements must not exceed five minutes in length, and a copy of the remarks should be forwarded to the above address one week in advance of the scheduled presentation date. Opportunities to present statements will be determined by the order in which requests are received.